Evidence and Pricing: Bridging the Comparative Effectiveness Gap in Federal and State Drug Policy - PubMed

3 hours ago

Comparative effectiveness research (CER) helps assess drug benefits in real-world settings.
Key gaps in using CER for pricing include fit-for-purpose evidence, transparency, and resources.
Recommendations for policymakers involve clear questions, PICOT frameworks, and transparent processes.
Manufacturers should leverage resources, ensure scientific credibility, and tailor evidence submissions.
Incorporating contemporary CER is essential for informing drug pricing negotiations and value assessments.

Hasty Briefsbeta